A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.
Epistemonikos ID: 6ce707e3e8754cb6abc65243f60c155dd8f7f5a5
First added on: May 14, 2024